Considering INQOVI

What is MDS?

The term "myelodysplastic syndromes (MDS)" refers to a group of conditions, which are sometimes called bone marrow failure disorders, that can lead to abnormalities in the blood. MDS occurs when bone marrow produces fewer healthy blood cells that work properly.

MDS is a rare type of blood cancer.

  • Up to 20,000 new cases of MDS are reported in the United States every year
  • Between 60,000 and 170,000 people in the United States are estimated to have MDS

MDS is not contagious. In very rare cases (up to 10%), MDS can be linked to inherited conditions (meaning they run in your family). Talk to your healthcare provider about inheritable disorders related to MDS.

Cross stitch of a vase of sunflowers

What are the risk factors of MDS?

The cause of MDS is unknown in more than 80% of diagnosed patients. You may be at greater risk of MDS if you:

  • Are older than 60 years (86% of patients with MDS are over 60)
  • Are male (men are more than twice as likely to develop MDS as women)
  • Have spent a lot of time around chemicals such as benzene (which can be found in tobacco smoke) or other toxic chemicals
  • Have received chemotherapy or radiation therapy for other cancers

How does INQOVI work?

INQOVI is an oral combination pill made of decitabine and cedazuridine. Decitabine has been used to treat MDS for many years, but was previously only available as an intravenous (IV) infusion. Cedazuridine is an ingredient that allows INQOVI to be taken by mouth.

In clinical trials, INQOVI was shown to be effective in some patients with myelodysplastic syndromes (MDS), including CMML.

CMML=chronic myelomonocytic leukemia

How can INQOVI help?

Cross stitch of an orchid in a flower pot

In a trial of 133 people, 21% had a complete response

Of the 57 people who needed blood transfusions* before starting the trial, 53% no longer required blood transfusions after treatment with INQOVI*

*In this trial, blood transfusions could mean either red blood cell or platelet transfusions. Patients who did not need blood transfusions were able to go without a transfusion for 56 days.

Who should take INQOVI?

INQOVI is for adult patients (18+ years of age). INQOVI was primarily studied in patients with intermediate- or high-risk types of myelodysplastic syndromes (MDS), including CMML. Your healthcare provider will determine if INQOVI can treat your type of MDS. It is not known if INQOVI is safe or effective in children.

The revised International Prognostic Scoring System is used to help predict the course of MDS in your body and your risk level for progressing to AML. Risk level (low, intermediate, high) is determined by your hemoglobin, blood cell counts, and genetic tests. You can talk to your healthcare provider about your risk level.

Be sure to talk to your healthcare provider before taking INQOVI if you

  • have kidney or liver problems
  • are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

AML=acute myeloid leukemia

Previous Page 


Next Page